--- title: 'Industry Daily Summary: What Happened on October 21, 2026' headline: Sanofi and ScionxBio partner on longer-lasting mRNA therapies description: The companies will test ScionxBio’s TERA platform with selected Sanofi candidates, without naming disease targets. url: https://thebench.bio/news/industry/2026-10-21 topic: industry date: '2026-10-21' covers: - '2026-10-21' date_published: '2026-10-21T12:05:40Z' date_modified: '2026-10-21T12:05:40Z' tags: - Industry sources: 1 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on October 21, 2026 **Sanofi and ScionxBio partner on longer-lasting mRNA therapies** The companies will test ScionxBio’s TERA platform with selected Sanofi candidates, without naming disease targets. ## Today in brief Sanofi and ScionxBio signed a global agreement to develop mRNA therapies that sustain protein production in the body. [1] ScionxBio will optimize candidates through in vivo validation, then Sanofi is set to lead later preclinical work, clinical development, manufacturing and commercialization. [1] ## Sanofi will take selected mRNA candidates into later development The collaboration will use ScionxBio’s TERA platform to develop extended-exposure formulations of selected Sanofi mRNA candidates. [1] TERA uses deep learning to assess relationships between molecular structure and activity in high-throughput screens. [1] ScionxBio will lead optimization through in vivo validation, testing candidates in living systems, before Sanofi takes on further preclinical work and studies to prepare candidates for clinical trials. [1] Sanofi is also set to handle clinical trials, manufacturing and global commercialization. [1] The engineered molecules are designed to resist enzymatic breakdown and sustain protein expression in the body. [1] The companies did not disclose disease targets. The approach concerns conditions that require sustained protein production, including inherited and acquired protein deficiencies. [1] ## Also published - [AbbVie races into F1 as pharma companies continue push into sport](), Pharmaceutical Technology - [New CCO Ogburn joins Cori Clinical](), Pharmafile ## Sources 1. [Sanofi and ScionxBio partner on mRNA therapies](), Pharmaceutical Technology, 2026-10-21 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: